Ridloff Elena — SEC insider filings

SEC reporting owner CIK 1772518. 31 insider filings on record with FilingPulse; latest filed 2026-09-18.

Transaction summary — filings shown

Covers all 31 filings on record, filed 2020-10-16 to 2026-09-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Kymera Therapeutics, Inc. (KYMR)Director14—7 legs · 31,500 sh · $2,063,86020
Sionna Therapeutics, Inc. (SION)CFO and CBO6—7 legs · 85,000 sh · $1,966,6346
ACADIA PHARMACEUTICALS INC (ACAD)EVP and CFO4—3 legs · 4,099 sh · $178,9757
Kronos Bio, Inc. (KRON)Director61 leg · 2,630 sh · $49,970—13
IMMUNIC, INC. (IMUX)Director1——1

Insider filings — Ridloff Elena

FiledFormIssuerReported transactionsSource
2026-09-184Sionna Therapeutics, Inc. (SION)Grant/award (A): 47,269 @ $0 · Grant/award (A): 47,268 @ $0 · Grant/award (A): 165,440 (derivative) @ $0 · Disposition to issuer (D): 165,440 (derivative) @ $0EDGAR
2026-08-104IMMUNIC, INC. (IMUX)Grant/award (A): 50,740 (derivative) @ $0EDGAR
2026-06-254Kymera Therapeutics, Inc. (KYMR)Grant/award (A): 6,068 (derivative) @ $0EDGAR
2026-05-114Kymera Therapeutics, Inc. (KYMR)Option exercise (M): 3,000 @ $31.20 · Sale (S): 3,000 @ $87 · Option exercise (M): 3,000 (derivative) @ $0EDGAR
2026-04-014Kymera Therapeutics, Inc. (KYMR)Option exercise (M): 7,400 @ $14.18 · Sale (S): 7,400 @ $85.37 · Option exercise (M): 4,600 @ $14.18 · Sale (S): 3,400 @ $85.19 · Sale (S): 1,200 @ $86.05 · Option exercise (M): 7,400 (derivative) @ $0 · +1 moreEDGAR
2026-01-064Sionna Therapeutics, Inc. (SION)Grant/award (A): 165,440 (derivative) @ $0EDGAR
2025-09-034Sionna Therapeutics, Inc. (SION)Sale (S): 748 @ $25.18 · Sale (S): 8,836 @ $25.08EDGAR
2025-08-284Sionna Therapeutics, Inc. (SION)Sale (S): 3,700 @ $25.13 · Sale (S): 3,618 @ $25.10 · Sale (S): 16,098 @ $25.97EDGAR
2025-08-214Sionna Therapeutics, Inc. (SION)Sale (S): 34,500 @ $21.08 · Sale (S): 17,500 @ $22.69EDGAR
2025-06-264Kymera Therapeutics, Inc. (KYMR)Grant/award (A): 16,000 (derivative) @ $0EDGAR
2025-06-204Kronos Bio, Inc. (KRON)Code (U): 25,296 @ $0.57 · Disposition to issuer (D): 25,879 (derivative) @ $0 · Disposition to issuer (D): 26,871 (derivative) @ $0 · Disposition to issuer (D): 15,450 (derivative) @ $0 · Disposition to issuer (D): 34,000 (derivative) @ $0 · Disposition to issuer (D): 17,000 (derivative) @ $0 · +1 moreEDGAR
2025-06-114Kymera Therapeutics, Inc. (KYMR)Option exercise (M): 4,500 @ $20.29 · Sale (S): 4,500 @ $50 · Option exercise (M): 4,500 (derivative) @ $0EDGAR
2025-06-034Kymera Therapeutics, Inc. (KYMR)Option exercise (M): 12,000 @ $27.67 · Sale (S): 7,200 @ $45.50 · Sale (S): 4,800 @ $47 · Option exercise (M): 12,000 (derivative) @ $0EDGAR
2025-02-104Sionna Therapeutics, Inc. (SION)Grant/award (A): 157,820 (derivative) @ $0EDGAR
2024-06-264Kronos Bio, Inc. (KRON)Grant/award (A): 11,333 @ $0 · Grant/award (A): 17,000 (derivative) @ $0EDGAR
2024-06-204Kymera Therapeutics, Inc. (KYMR)Grant/award (A): 16,000 (derivative) @ $0EDGAR
2023-06-264Kronos Bio, Inc. (KRON)Grant/award (A): 11,333 @ $0 · Grant/award (A): 17,000 (derivative) @ $0EDGAR
2023-06-204Kymera Therapeutics, Inc. (KYMR)Grant/award (A): 12,000 (derivative) @ $0EDGAR
2022-07-014Kymera Therapeutics, Inc. (KYMR)Grant/award (A): 9,000 (derivative) @ $0EDGAR
2022-06-294Kronos Bio, Inc. (KRON)Grant/award (A): 34,000 (derivative) @ $0EDGAR
2022-06-164Kymera Therapeutics, Inc. (KYMR)Grant/award (A): 12,000 (derivative) @ $0EDGAR
2022-04-154/AKymera Therapeutics, Inc. (KYMR)Grant/award (A): 20,919 (derivative) @ $0EDGAR
2022-04-154/AKymera Therapeutics, Inc. (KYMR)Grant/award (A): 10,459 (derivative) @ $0EDGAR
2021-06-234Kronos Bio, Inc. (KRON)Grant/award (A): 15,450 (derivative) @ $0EDGAR
2021-06-174Kymera Therapeutics, Inc. (KYMR)Grant/award (A): 20,063 (derivative) @ $0EDGAR
2021-04-304ACADIA PHARMACEUTICALS INC (ACAD)Option exercise (M): 3,245 · Sale (S): 1,032 @ $20.33 · Option exercise (M): 3,245 (derivative) @ $0EDGAR
2021-03-164Kymera Therapeutics, Inc. (KYMR)Grant/award (A): 40,127 (derivative) @ $0EDGAR
2021-02-254ACADIA PHARMACEUTICALS INC (ACAD)Grant/award (A): 36,231 (derivative) @ $0 · Grant/award (A): 9,839 (derivative) @ $0EDGAR
2021-02-084ACADIA PHARMACEUTICALS INC (ACAD)Grant/award (A): 6,490 @ $0 · Sale (S): 2,051 @ $50.61EDGAR
2021-01-084ACADIA PHARMACEUTICALS INC (ACAD)Option exercise (M): 2,722 · Sale (S): 1,016 @ $53.34 · Option exercise (M): 1,016 (derivative) @ $0EDGAR
2020-10-164Kronos Bio, Inc. (KRON)Purchase (P): 2,630 @ $19EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-10-16 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1772518 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs